Lumida
/MD
⌘K
Pediatrix Medical Group Inc

Pediatrix Medical Group Inc

MD
$26.13USD↓-0.80%-0.21 today

MARKET CAP

2.1B

P/E (TTM)

12.2x

FWD P/E

11.2x

DAY RANGE

$26 – $27

52W RANGE

$12
$28

AI Summary

Stalk
Buy NowMedium

MD is in a Stage 2 advancing uptrend with rising EMAs and the 50 DMA providing dynamic support. The recent corrective pullback held at the 21 EMA and 50 DMA, repairing the 9/21 EMA structure and attracting supportive volume on the bounce. Short-term price is now pulling into rising EMAs without exhaustion, offering a favorable buying opportunity near structural support under the Growth at Reasonable Price strategy.

  • ↑Q1 adj. EBITDA $58M beats estimates; revenue +3% YoY driven by pricing
  • ↑Executed $21M buybacks; cash >$200M and net debt ~$385M, leverage ~1.3x
  • ↓Same-unit volumes fell, notably in NICU, risking future revenue growth
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Pediatrix Medical Group, Inc. (NYSE:MD) operates as a pediatric healthcare provider specializing in critical care services for mothers and children, holding a dominant position through its extensive network of hospital partnerships. The company is actively involved in neonatology and maternal-fetal medicine, positioning itself amidst favorable trends towards specialized pediatric care and an increasing demand for its services in a complex healthcare landscape.

Bull says

  • ↑Q1 adj. EBITDA $58M beats estimates; revenue +3% YoY driven by pricing
  • ↑Executed $21M buybacks; cash >$200M and net debt ~$385M, leverage ~1.3x
  • ↑Pricing increased 4% via RCM efficiencies, improving payer mix health
  • ↑Industry leader in neonatology with broad hospital partnerships and telehealth push
  • ↑High earnings yield, strong momentum factors, manageable leverage support valuation
  • ↑Guidance reaffirmed: $280–300M adj. EBITDA for 2026 underpins growth thesis

Bear says

  • ↓Same-unit volumes fell, notably in NICU, risking future revenue growth
  • ↓Potential ACA subsidy lapses create regulatory headwinds for patient volumes
  • ↓Salaries and incentive costs rose, compressing profit margins in Q1
  • ↓Downward growth factors and cautious analyst revisions signal limited earnings upside
  • ↓Low dividend returns and balance sheet vulnerabilities add investor caution
  • ↓Recent stock price drop and thin trading volumes reflect market skepticism

Investment themes with MD

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-08-2026neutral

Transcript signals

Bull points

  • We were pleased with our strong first quarter results, driven by top-line growth with adjusted EBITDA coming in at $58 million.
  • Given the uncertainty of whether we will experience this headwind, and since it's still early in the year, we are reaffirming our full 2026 outlook of $280 to $300 million in adjusted EBITDA.
  • I will say that the recent acquisitions we've made have done better than our initial projections, so we're very happy about that.

Bear points

  • We know that major hospital systems have seen a decline in patient volume and revenue, and we may see that in the future.
  • So Cassandra is right that the environment for hospitals is tougher than it has been, which just makes us make sure that we're offering the service that hospitals find very valuable and irreplaceable.
  • So Cassandra is right that the environment for hospitals is tougher than it has been, which just makes us make sure that we're offering the service that hospitals find very valuable and irreplaceable.
Read full transcript analysis ›